VRNA vs. LQDA, INVA, TYRA, IRWD, SAVA, OCUL, ELVN, BCYC, ARQT, and OPK
Should you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Liquidia (LQDA), Innoviva (INVA), Tyra Biosciences (TYRA), Ironwood Pharmaceuticals (IRWD), Cassava Sciences (SAVA), Ocular Therapeutix (OCUL), Enliven Therapeutics (ELVN), Bicycle Therapeutics (BCYC), Arcutis Biotherapeutics (ARQT), and OPKO Health (OPK). These companies are all part of the "pharmaceutical preparations" industry.
Liquidia (NASDAQ:LQDA) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking.
Verona Pharma has a net margin of 0.00% compared to Verona Pharma's net margin of -674.42%. Liquidia's return on equity of -25.09% beat Verona Pharma's return on equity.
Verona Pharma received 126 more outperform votes than Liquidia when rated by MarketBeat users. Likewise, 79.95% of users gave Verona Pharma an outperform vote while only 66.55% of users gave Liquidia an outperform vote.
Liquidia has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.43, suggesting that its stock price is 57% less volatile than the S&P 500.
In the previous week, Verona Pharma had 1 more articles in the media than Liquidia. MarketBeat recorded 4 mentions for Verona Pharma and 3 mentions for Liquidia. Verona Pharma's average media sentiment score of 1.45 beat Liquidia's score of 1.11 indicating that Liquidia is being referred to more favorably in the media.
Liquidia currently has a consensus price target of $21.00, indicating a potential upside of 70.87%. Verona Pharma has a consensus price target of $33.20, indicating a potential upside of 167.10%. Given Liquidia's stronger consensus rating and higher possible upside, analysts clearly believe Verona Pharma is more favorable than Liquidia.
Verona Pharma has lower revenue, but higher earnings than Liquidia. Verona Pharma is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.
64.5% of Liquidia shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma shares are owned by institutional investors. 31.6% of Liquidia shares are owned by company insiders. Comparatively, 4.8% of Verona Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Verona Pharma beats Liquidia on 13 of the 17 factors compared between the two stocks.
Get Verona Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verona Pharma Competitors List
Related Companies and Tools
